MeMed, an Israeli biomedical company
MeMed, an Israeli biomedical company that developed a unique blood test for rapid diagnosis of a bacterial or viral infection that can significantly reduce the use of antibiotics, has received a unique USD 9.3 million development contract from the US Department of Defense to finance the completion of the company's second-generation technology. 
The matter was led by Partners Arnon Samborsky and Daniela Ben Shalom from our firm. We have been representing MeMed since its inception. Http://